🇺🇸 FDA
Patent

US 12221462

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12221462 (Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells) held by Allogene Therapeutics, Inc. expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Allogene Therapeutics, Inc.
Grant date
Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K2239/23